These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 32012149)

  • 1. Mutational processes of distinct POLE exonuclease domain mutants drive an enrichment of a specific TP53 mutation in colorectal cancer.
    Fang H; Barbour JA; Poulos RC; Katainen R; Aaltonen LA; Wong JWH
    PLoS Genet; 2020 Feb; 16(2):e1008572. PubMed ID: 32012149
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Somatic POLE exonuclease domain mutations are early events in sporadic endometrial and colorectal carcinogenesis, determining driver mutational landscape, clonal neoantigen burden and immune response.
    Temko D; Van Gool IC; Rayner E; Glaire M; Makino S; Brown M; Chegwidden L; Palles C; Depreeuw J; Beggs A; Stathopoulou C; Mason J; Baker AM; Williams M; Cerundolo V; Rei M; Taylor JC; Schuh A; Ahmed A; Amant F; Lambrechts D; Smit VT; Bosse T; Graham TA; Church DN; Tomlinson I
    J Pathol; 2018 Jul; 245(3):283-296. PubMed ID: 29604063
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The interaction between cytosine methylation and processes of DNA replication and repair shape the mutational landscape of cancer genomes.
    Poulos RC; Olivier J; Wong JWH
    Nucleic Acids Res; 2017 Jul; 45(13):7786-7795. PubMed ID: 28531315
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical and epigenetic features of colorectal cancer patients with somatic POLE proofreading mutations.
    Kawai T; Nyuya A; Mori Y; Tanaka T; Tanioka H; Yasui K; Toshima T; Taniguchi F; Shigeyasu K; Umeda Y; Fujiwara T; Okawaki M; Yamaguchi Y; Goel A; Nagasaka T
    Clin Epigenetics; 2021 May; 13(1):117. PubMed ID: 34034807
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High mutational burden in colorectal carcinomas with monoallelic POLE mutations: absence of allelic loss and gene promoter methylation.
    Hühns M; Nürnberg S; Kandashwamy KK; Maletzki C; Bauer P; Prall F
    Mod Pathol; 2020 Jun; 33(6):1220-1231. PubMed ID: 31857678
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The somatic POLE P286R mutation defines a unique subclass of colorectal cancer featuring hypermutation, representing a potential genomic biomarker for immunotherapy.
    Ahn SM; Ansari AA; Kim J; Kim D; Chun SM; Kim J; Kim TW; Park I; Yu CS; Jang SJ
    Oncotarget; 2016 Oct; 7(42):68638-68649. PubMed ID: 27612425
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exonuclease mutations in DNA polymerase epsilon reveal replication strand specific mutation patterns and human origins of replication.
    Shinbrot E; Henninger EE; Weinhold N; Covington KR; Göksenin AY; Schultz N; Chao H; Doddapaneni H; Muzny DM; Gibbs RA; Sander C; Pursell ZF; Wheeler DA
    Genome Res; 2014 Nov; 24(11):1740-50. PubMed ID: 25228659
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ultra-mutated colorectal cancer patients with POLE driver mutations exhibit distinct clinical patterns.
    Hu H; Cai W; Wu D; Hu W; Dong Wang L; Mao J; Zheng S; Ge W
    Cancer Med; 2021 Jan; 10(1):135-142. PubMed ID: 33125191
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of the cancer-associated DNA polymerase ε P286R in fission yeast leads to translesion synthesis polymerase dependent hypermutation and defective DNA replication.
    Soriano I; Vazquez E; De Leon N; Bertrand S; Heitzer E; Toumazou S; Bo Z; Palles C; Pai CC; Humphrey TC; Tomlinson I; Cotterill S; Kearsey SE
    PLoS Genet; 2021 Jul; 17(7):e1009526. PubMed ID: 34228709
    [TBL] [Abstract][Full Text] [Related]  

  • 10. POLE somatic mutations in advanced colorectal cancer.
    Guerra J; Pinto C; Pinto D; Pinheiro M; Silva R; Peixoto A; Rocha P; Veiga I; Santos C; Santos R; Cabreira V; Lopes P; Henrique R; Teixeira MR
    Cancer Med; 2017 Dec; 6(12):2966-2971. PubMed ID: 29072370
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinicopathological and mutational analyses of colorectal cancer with mutations in the POLE gene.
    Hino H; Shiomi A; Kusuhara M; Kagawa H; Yamakawa Y; Hatakeyama K; Kawabata T; Oishi T; Urakami K; Nagashima T; Kinugasa Y; Yamaguchi K
    Cancer Med; 2019 Aug; 8(10):4587-4597. PubMed ID: 31240875
    [TBL] [Abstract][Full Text] [Related]  

  • 12. POLE and POLD1 screening in 155 patients with multiple polyps and early-onset colorectal cancer.
    Esteban-Jurado C; Giménez-Zaragoza D; Muñoz J; Franch-Expósito S; Álvarez-Barona M; Ocaña T; Cuatrecasas M; Carballal S; López-Cerón M; Marti-Solano M; Díaz-Gay M; van Wezel T; Castells A; Bujanda L; Balmaña J; Gonzalo V; Llort G; Ruiz-Ponte C; Cubiella J; Balaguer F; Aligué R; Castellví-Bel S
    Oncotarget; 2017 Apr; 8(16):26732-26743. PubMed ID: 28423643
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High frequency of POLE mutations in synchronous endometrial and ovarian carcinoma.
    Ishikawa M; Nakayama K; Nakamura K; Ono R; Yamashita H; Ishibashi T; Minamoto T; Iida K; Razia S; Ishikawa N; Kyo S
    Hum Pathol; 2019 Mar; 85():92-100. PubMed ID: 30448219
    [TBL] [Abstract][Full Text] [Related]  

  • 14. POLE Mutation Spectra Are Shaped by the Mutant Allele Identity, Its Abundance, and Mismatch Repair Status.
    Hodel KP; Sun MJS; Ungerleider N; Park VS; Williams LG; Bauer DL; Immethun VE; Wang J; Suo Z; Lu H; McLachlan JB; Pursell ZF
    Mol Cell; 2020 Jun; 78(6):1166-1177.e6. PubMed ID: 32497495
    [TBL] [Abstract][Full Text] [Related]  

  • 15. POLE and POLD1 germline exonuclease domain pathogenic variants, a rare event in colorectal cancer from the Middle East.
    Siraj AK; Bu R; Iqbal K; Parvathareddy SK; Masoodi T; Siraj N; Al-Rasheed M; Kong Y; Ahmed SO; Al-Obaisi KAS; Victoria IG; Arshad M; Al-Dayel F; Abduljabbar A; Ashari LH; Al-Kuraya KS
    Mol Genet Genomic Med; 2020 Aug; 8(8):e1368. PubMed ID: 32567205
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pathological complete response to immune checkpoint inhibitor in patients with colorectal cancer liver metastases harboring
    Wen L; Chen Z; Ji X; Fong WP; Shao Q; Ren C; Cai Y; Li B; Yuan Y; Wang D; Li Y
    J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35793867
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Somatic POLE proofreading domain mutation, immune response, and prognosis in colorectal cancer: a retrospective, pooled biomarker study.
    Domingo E; Freeman-Mills L; Rayner E; Glaire M; Briggs S; Vermeulen L; Fessler E; Medema JP; Boot A; Morreau H; van Wezel T; Liefers GJ; Lothe RA; Danielsen SA; Sveen A; Nesbakken A; Zlobec I; Lugli A; Koelzer VH; Berger MD; Castellví-Bel S; Muñoz J; ; de Bruyn M; Nijman HW; Novelli M; Lawson K; Oukrif D; Frangou E; Dutton P; Tejpar S; Delorenzi M; Kerr R; Kerr D; Tomlinson I; Church DN
    Lancet Gastroenterol Hepatol; 2016 Nov; 1(3):207-216. PubMed ID: 28404093
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Morphological, immunophenotypical and molecular features of hypermutation in colorectal carcinomas with mutations in DNA polymerase ε (POLE).
    Forgó E; Gomez AJ; Steiner D; Zehnder J; Longacre TA
    Histopathology; 2020 Feb; 76(3):366-374. PubMed ID: 31479159
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular profiling and sequential somatic mutation shift in hypermutator tumours harbouring POLE mutations.
    Hatakeyama K; Ohshima K; Nagashima T; Ohnami S; Ohnami S; Serizawa M; Shimoda Y; Maruyama K; Akiyama Y; Urakami K; Kusuhara M; Mochizuki T; Yamaguchi K
    Sci Rep; 2018 Jun; 8(1):8700. PubMed ID: 29880869
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Polymerase Epsilon Exonuclease Domain Mutations in Ovarian Endometrioid Carcinoma.
    Hoang LN; McConechy MK; Köbel M; Anglesio M; Senz J; Maassen M; Kommoss S; Meng B; Postovit L; Kelemen LE; Staebler A; Brucker S; Krämer B; McAlpine JN; Gilks CB; Huntsman DG; Lee CH
    Int J Gynecol Cancer; 2015 Sep; 25(7):1187-93. PubMed ID: 26166557
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.